US2081934A - Cinnamic preparations for therapeutic uses - Google Patents
Cinnamic preparations for therapeutic uses Download PDFInfo
- Publication number
- US2081934A US2081934A US51270A US5127035A US2081934A US 2081934 A US2081934 A US 2081934A US 51270 A US51270 A US 51270A US 5127035 A US5127035 A US 5127035A US 2081934 A US2081934 A US 2081934A
- Authority
- US
- United States
- Prior art keywords
- cinnamic
- ester
- benzyl
- preparations
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
Definitions
- the invention relates to therapeutic, preparations adapted for intramuscular or subcutaneous injections and containing benzyl cinnamic ester.
- the object of the invention is to effect improvethe use of this the action of the benzyl ester of cinnamic acid has beneficial effects in connection with the treatment of a variety of diseased conditions of the humanbody has been siderable investigation and study and many publications bearing on the, subject are extant. Among such publications may be mentioned the following:
- benzyl cinnamic ester 5 benzyl alcohol and cinnamicacid,althoughmean- 10 not derived from the cinnamic ester, and cinnamic acid resulting from the presence in the composition of the ethyl cinnamic ester.
- Dosages of the preparation are then filled in ampules and sterilized.
- the ordinary dosefor a normal patient is 1 cc., while for a less healthy patient a dose of V2 cc. is ordinarily used.
- the dose for children is ordinarily /4 cc.
- the preferred administration of the product is by way of intramuscular or subcutaneous-injection.
- the efl'ect is in itself particularly" with respect to micro-orsanisms such as those of tetanus and diphtheria, though the preparationvis not to be regarded as a speciijlc for these organisms.
- the fields of use and the type of diseased with which their use geous is that which is tions hereinabove referred to.
- the method of preparing a therapeutic preparation which comprises establishing a solution of benzyl cinnamlc ester in henzyl alcohol in the general relation of 20 grams of the former-in about 15cc. of the latter and then incorporating the said solution with olive oil in the approximate proportion of 3.2 of the solution in 100 parts of the product, introducing dosages of the product into. ampules and sterilizing.
- the method or preparing a therapeutic preparation which comprises establishing a solution of benzyl cinnamic ester in benzyl alcohol in a general relation of 20 grams of the former in about 15 cc. of the latter, adding a cinnamic ester each gram of the benz yl other than the benzyl to said solution in the approximate proportion of of 1 cc. of said ester per gramot the benzyl cinnamic ester, introduclng dosages of the sterilizing.
- the method of preparing a therapeutic preparation which comprises establishing a solution of benzyl cinnamic, ester in benzyl alcohol product into ampules and in a general relation of 20 grams'oi the former in of the latter, adding ethyl cinnamic. solution in the approidmate propor- JAGOE JACOBSON.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
-Patented June 1, 1937 v zios sai PEUTIC USES 'CINNAMIO PREPARATIONS FOB f iacobJacobsom-Paris, France NoDrawing ggplication November 23, 1935,
rial No. 5
I 5 Claims. The invention relates to therapeutic, preparations adapted for intramuscular or subcutaneous injections and containing benzyl cinnamic ester. The object of the invention is to effect improvethe use of this the action of the benzyl ester of cinnamic acid has beneficial effects in connection with the treatment of a variety of diseased conditions of the humanbody has been siderable investigation and study and many publications bearing on the, subject are extant. Among such publications may be mentioned the following:
Comptes Rendue Soc. de Dermatologie of I February 9, 1922.-'Articles by Darier and Jean-.
selme and Jacobson;
Bulletin et Mm. de la Soc. md. des HQpJ, Reports of the Sessions of October 23, 1925, March 25, 1927, and April 19, 19 29; La Presse Mdicale, of March 13,
a by Gosset, Gutmann and Iahel; Paris Mdical, of qctober 25, 1930.--Article by 2 LVy-Solal, et a1.
Publication by Socit dOphtalmologie de Paris of February 1931; Articleby Chevallereau 8: 88891; La Tunisie Mdicale, April, 1932.--Report of the Commission de Tunisie. i a 30 Revenue Internationale du Trachomes, of January, 1932, and April, 1933, by Jean-Sedan. l
Archives de Mdecine et de Pharmacie Mili-q taires of February, 1933.-Article "by Barrel (8:
sm-mine Luc. rtevu r ntemationaie du Traohome of April,
1933- cle by Junes.
Bulletin of the'A cademy of Medicine.'-Report of the Session of July 18, 1933, Volume 110, No. 28 40 on Regression des kratites, etc." I According to published information on the-subject, the preparation employed is ordinarily. a solution or what is known in French as "ether benzyl cinnamique in olive oil in the proportion of 3.2 parts in one volume. In the French 45 hundred parts by a modern English chemical terminology word ether" in the combination represented by the- English word ester. The benzylic ester of cinnamic acid is, however, a. substance which is very difllcuitly soluble in olive oil.
50 I found that better results are obtainableif the percentage of 3.2 of the benzylic ester of cinnamic acid is reduced and in part replaced, within the approximate totality of 3.2 parts, by other ingredients, provided such other ments in products of the stated character with. reference to the physiological effects produced bytype of material. The fact that made the subject of constated would be ingredients are of such character as to contribute one or both of benzyl alcohol and cinnamic acid radicals. For example, if in-the non-oil parts ofthe product there are present in the following relation the following substances, (about 20 grams) benzyl alcohol (about 10-15 cc.) and ethyl cinnamic ester (about 2 co.) the 1111511 mate effect in the human body will apparently be a decomposition of the benzyl cinnamic ester into the,
to wit. benzyl cinnamic ester 5 benzyl alcohol and cinnamicacid,althoughmean- 10 not derived from the cinnamic ester, and cinnamic acid resulting from the presence in the composition of the ethyl cinnamic ester. position alsogre'atly facilitate the-production of a suspension or solution in olive oil inasmuch as a properly prepared solution of the benzyl cinnamic ester in benzyl alcohol, under avoidance of The components of the new com- 15 fusion of the benzyl cinnamic ester in an environ- 20 ment other than benzyl alcohol with the addition of the ethyl cinnamic ester, all in the approximate proportions stated, can be readily incorporated in pure refined olive oil. In the oil suspension the stated mixture of non-oil components preferably constitute about 3.2 parts in one hundred.
Dosages of the preparation are then filled in ampules and sterilized. The ordinary dosefor a normal patient is 1 cc., while for a less healthy patient a dose of V2 cc. is ordinarily used. The dose for children is ordinarily /4 cc. The preferred administration of the product is by way of intramuscular or subcutaneous-injection. The efl'ect is in itself particularly" with respect to micro-orsanisms such as those of tetanus and diphtheria, though the preparationvis not to be regarded as a speciijlc for these organisms. The fields of use and the type of diseased with which their use geous is that which is tions hereinabove referred to.
I claim:
1. A sterilized preparatiorf'constituted of an olive oil suspension of a mixture containing benzyl cinnamic ester and benzyl alcoholin the approximate relation of 20 grams of the former in 15 cc. of the latter and with a total of suspended material approxiis particularly advantain claim 1 in which the non-oily componen -elude ethyl cinnamic indicated by the publicaharmless and even anti-toxic,
conditions in connection ampule-contained therapeutic lation of of 1 cc. for cinnamic ester.
3. The method of preparing a therapeutic preparation which comprises establishing a solution of benzyl cinnamlc ester in henzyl alcohol in the general relation of 20 grams of the former-in about 15cc. of the latter and then incorporating the said solution with olive oil in the approximate proportion of 3.2 of the solution in 100 parts of the product, introducing dosages of the product into. ampules and sterilizing.
4. The method or preparing a therapeutic preparation which comprises establishing a solution of benzyl cinnamic ester in benzyl alcohol in a general relation of 20 grams of the former in about 15 cc. of the latter, adding a cinnamic ester each gram of the benz yl other than the benzyl to said solution in the approximate proportion of of 1 cc. of said ester per gramot the benzyl cinnamic ester, introduclng dosages of the sterilizing.
5. The method of preparing a therapeutic preparation which comprises establishing a solution of benzyl cinnamic, ester in benzyl alcohol product into ampules and in a general relation of 20 grams'oi the former in of the latter, adding ethyl cinnamic. solution in the approidmate propor- JAGOE JACOBSON.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US51270A US2081934A (en) | 1935-11-23 | 1935-11-23 | Cinnamic preparations for therapeutic uses |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US51270A US2081934A (en) | 1935-11-23 | 1935-11-23 | Cinnamic preparations for therapeutic uses |
Publications (1)
Publication Number | Publication Date |
---|---|
US2081934A true US2081934A (en) | 1937-06-01 |
Family
ID=21970269
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US51270A Expired - Lifetime US2081934A (en) | 1935-11-23 | 1935-11-23 | Cinnamic preparations for therapeutic uses |
Country Status (1)
Country | Link |
---|---|
US (1) | US2081934A (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2592149A (en) * | 1949-04-09 | 1952-04-08 | Jacobson Jacob | Therapeutic preparation comprising benzyl cinnamate and vitamin a |
US2675342A (en) * | 1950-09-30 | 1954-04-13 | Schering Corp | Supersaturated oil solutions of steroid hormones |
US3105793A (en) * | 1956-11-28 | 1963-10-01 | Lobel Mervyn Joseph | Injectable medicinal composition |
-
1935
- 1935-11-23 US US51270A patent/US2081934A/en not_active Expired - Lifetime
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2592149A (en) * | 1949-04-09 | 1952-04-08 | Jacobson Jacob | Therapeutic preparation comprising benzyl cinnamate and vitamin a |
US2675342A (en) * | 1950-09-30 | 1954-04-13 | Schering Corp | Supersaturated oil solutions of steroid hormones |
US3105793A (en) * | 1956-11-28 | 1963-10-01 | Lobel Mervyn Joseph | Injectable medicinal composition |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE2513797C2 (en) | PHARMACEUTICAL COMPOSITION | |
US4798846A (en) | Pharmaceutical compositions | |
CH693764A5 (en) | A pharmaceutical composition comprising propofol and edetate. | |
US3070499A (en) | Parenteral aqueous solutions of fat soluble vitamins | |
JP2000273061A (en) | Terpenoid emulsion | |
EP0163924B1 (en) | Vitamin medicine for the treatment and protection of mucous membranes, and use of vitamin e for manufacturing the medicine | |
US2081934A (en) | Cinnamic preparations for therapeutic uses | |
JPH05501542A (en) | Use of C-20 to C-26 fatty alcohols in the treatment of viral infections | |
Modell | Drugs in Current Use 1958 | |
DE2262427A1 (en) | IMMUNOSTIMULATING AGENT AND METHOD FOR PREPARING IT | |
EP0238198A2 (en) | Method of modifying the lipid structure function and expression of cell membranes and pharmaceutical compositions for use therein | |
US2744851A (en) | Cardiac glycosides for intramuscular injection | |
US3894153A (en) | Method of medical treatment of asthma | |
US2916417A (en) | Article of manufacture | |
US3885030A (en) | Medicine comprising lysine by-products | |
US3781422A (en) | Therapeutic solution of iron and liposoluble vitamins | |
Winter et al. | Effect of steroids upon resistance of skin to intracutaneous injection | |
US3032468A (en) | Method particularly suitable for the prevention of paresis puerperalis in cattle | |
Mostert et al. | Observations on the haemolytic activity of guaiacol glycerol ether | |
EP3328356A1 (en) | Concentrate containing alprostadil | |
US2592149A (en) | Therapeutic preparation comprising benzyl cinnamate and vitamin a | |
Friedlander et al. | Studies in thrombo-angiitis obliterans (Buerger) X. Reduction in blood volume following bilateral oophorectomy | |
Crankshaw et al. | The short term distribution of thiopentone in the dog | |
CN112315901A (en) | Concentrated solution for injection and preparation method thereof | |
Shonle | The Chemical Basis of Hypnotic Action as an Index of Clinical Efficiency. |